These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11338055)

  • 21. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats.
    Lopez-Talavera JC; Merrill WW; Groszmann RJ
    Gastroenterology; 1995 Mar; 108(3):761-7. PubMed ID: 7875478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of portacaval surgical anastomosis on systemic and splanchnic hemodynamics in portal hypertensive, cirrhotic rats.
    Romeo JM; López-Farré A; Martín-Paredero V; López-Novoa JM
    Can J Physiol Pharmacol; 1988 Dec; 66(12):1493-8. PubMed ID: 3228783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats.
    Muñoz J; Albillos A; Pérez-Páramo M; Rossi I; Alvarez-Mon M
    Am J Physiol; 1999 Mar; 276(3):G687-93. PubMed ID: 10070045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathophysiology of portal hypertension.
    Gupta TK; Chen L; Groszmann RJ
    Clin Liver Dis; 1997 May; 1(1):1-12. PubMed ID: 15562664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemodynamic alterations in cirrhosis and portal hypertension.
    Kim MY; Baik SK; Lee SS
    Korean J Hepatol; 2010 Dec; 16(4):347-52. PubMed ID: 21415576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathophysiology of portal hypertension.
    Bosch J; Pizcueta P; Feu F; Fernández M; García-Pagán JC
    Gastroenterol Clin North Am; 1992 Mar; 21(1):1-14. PubMed ID: 1568769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats.
    Wiest R; Shah V; Sessa WC; Groszmann RJ
    Am J Physiol; 1999 Apr; 276(4):G1043-51. PubMed ID: 10198349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
    Fernandez M; Mejias M; Garcia-Pras E; Mendez R; Garcia-Pagan JC; Bosch J
    Hepatology; 2007 Oct; 46(4):1208-17. PubMed ID: 17654489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of nitric oxide and cyclooxygenase inhibition on splanchnic hemodynamics in portal hypertension.
    Wu Y; Burns RC; Sitzmann JV
    Hepatology; 1993 Dec; 18(6):1416-21. PubMed ID: 8244267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension.
    Iwakiri Y
    J Clin Gastroenterol; 2007; 41 Suppl 3():S288-94. PubMed ID: 17975478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmented endogenous nitric oxide production in partial portal vein-ligated rats.
    Hori N; Takahashi H; Okanoue T; Sawa Y; Mori T; Takami S; Yoshimura M; Kashima K
    Clin Exp Pharmacol Physiol; 1995 Aug; 22(8):506-11. PubMed ID: 7586705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of effect of indomethacin on systemic and splanchnic haemodynamics in portal hypertensive rats.
    Blanchart A; Hernando N; Fernández-Muñoz D; Hernando L; López-Novoa JM
    Clin Sci (Lond); 1985 May; 68(5):605-7. PubMed ID: 3884241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Portal hemodynamics in chronic liver disease.
    Nagral A; Patch D; Burroughs AK
    Indian J Gastroenterol; 1999; 18(2):78-83. PubMed ID: 10319539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hyperdynamic status in a partial portal vein ligated (PVL) rat's portal hypertension model].
    Wang CT; Kuang YL; Chen ZP
    Zhonghua Wai Ke Za Zhi; 1994 Sep; 32(9):573-5. PubMed ID: 7720436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis.
    Martin PY; Ginès P; Schrier RW
    N Engl J Med; 1998 Aug; 339(8):533-41. PubMed ID: 9709047
    [No Abstract]   [Full Text] [Related]  

  • 36. [Portal hypertension and the endothelium].
    Marecková Z; Horký K
    Cesk Fysiol; 2001 Feb; 50(1):19-24. PubMed ID: 11268558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis.
    Gatta A; Bolognesi M; Merkel C
    Mol Aspects Med; 2008; 29(1-2):119-29. PubMed ID: 18036654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats.
    Heller J; Shiozawa T; Trebicka J; Hennenberg M; Schepke M; Neef M; Sauerbruch T
    Eur J Clin Invest; 2003 Nov; 33(11):1006-12. PubMed ID: 14636305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Splanchnic hyposensitivity to glypressin in a hemorrhage-transfused common bile duct-ligated rat model of portal hypertension: role of nitric oxide and bradykinin.
    Chen CT; Chu CJ; Lee FY; Chang FY; Wang SS; Lin HC; Hou MC; Wu SL; Chan CC; Huang HC; Lee SD
    Hepatogastroenterology; 2009; 56(94-95):1261-7. PubMed ID: 19950773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathophysiology of portal hypertension.
    Cichoz-Lach H; Celiński K; Słomka M; Kasztelan-Szczerbińska B
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():231-8. PubMed ID: 18812641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.